The aim of this study of 53 persons with bipolar disorder (BD) was to evaluate the relationship between history of exposure to antidepressants (AD) and mood stabilizers (MS) and the percentage of time spent ill.
Methods
BD outpatients with more than 12 months of prospective follow-up were included. Outcome was documented using a life charting technique. Current and previous exposure to AD and MS were assessed using a scale that provides a quantitative measure of exposure to psychotropic medications. Regression models were used to correct for possible confounders.
Results
Previous treatment with AD was an independent predictor of polarity changes (P < .001) and mixed symptoms (P = .01). In contrast, “years of exposure to MS” was an independent predictor of time spent asymptomatic (P = .019). The ratio between exposure to AD vs MS was associated with less weeks asymptomatic (P = .03), more mixed symptomatology (P = .019), and more polarity changes (P = .001).
Conclusions
Antidepressant exposure was a major predictor of mood instability in the long-term outcome of BD. The ratio used of previous exposure to AD vs MS was associated with poor outcomes, suggesting that the harmful effect of AD may be additive and related to how much they are used.
BaldessariniRJ, LeahyL, ArconaS, . Patterns of psychotropic drug prescription for U. S. patients with diagnoses of bipolar disorders. Psychiatr Serv. 2007;58:85–91.
2.
WehrTA, GoodwinFK.Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry. 1979;36:555–559.
3.
WehrTA, SackDA, RosenthalNE, . Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry. 1988;145:179–184.
4.
QuitkinFM, KaneJ, RifkinA, . Prophylactic lithium carbonate with and without imipramine for bipolar 1 patients. A double-blind study. Arch Gen Psychiatry. 1981;38:902–907.
5.
KukopulosA, ReginaldiD, LaddomadaP, . Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol. 1980;13:156–167.
6.
AltshulerLL, PostRM, LeverichGS, . Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry. 1995;152:1130–1138.
7.
GhaemiSN, BoimanEE, GoodwinFK.Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry. 2000;61:804–808.
8.
YoungLT, JoffeRT, RobbJC, . Double-blind comparison of addition of a second mood stabilizer vs an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry. 2000;157:124–126.
9.
NemeroffCB, EvansDL, GyulaiL, . Doubleblind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158:906–912.
10.
AltshulerL, KiriakosL, CalcagnoG, . The impact of antidepressants discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. J Clin Psychiatry. 2001;62:612–616.
11.
LeverichGS, AltshulerLL, FryeMA, . Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006;163:232–239.
12.
SachsGS, NierenbergAA, CalabreseJR, . Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356:1711–1722.
13.
HarveyPD.Defining and achieving recovery from bipolar disorder. J Clin Psychiatry. 2006;67:(suppl 9)14–18.
14.
GhaemiSN, RosenquistKJ, KoJY, . Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry. 2004;161:163–165.
15.
MundoE, CattaneoE, RussoM, . Clinical variables related to antidepressant-induced mania in bipolar disorder. J Affect Disord. 2006;92:227–230.
16.
FirstM, SpitzerR, GibbonM, . Structured Clinical Interview for DSM-IV Axis Disorders I—Clinical Version (SCID-CV).Washington, DC:American Psychiatric Press; 1996.
17.
Ramos-BrievaJA, Cordero-VillafafilaA.A new validation of the Hamilton Rating Scale for Depression. J Psychiatr Res. 1988;22:21–28.
18.
ColomF, VietaE, Martínez-AránA, . Spanish version of a scale for the assessment of mania: validity and reliability of the Young Mania Rating Scale [in Spanish]. Med Clin (Barc). 2002;119:366–371.
19.
MartinoDJ, MarengoE, IgoaA, . Neurocognitive and symptomatic predictors of functional outcome in bipolar disorders: a prospective 1 year follow-up study. J Affect Disord. 2009;116:37–42.
20.
PeraltaV, CuestaM.Escala Clínica de Intensidad, Frecuencia y Duración del Tratamiento Psicofarmacológico (Escala IFD).Pamplona, Spain: Virgen del Camino Hospital; 2002.
21.
GijsmanHJ, GeddesJR, RendellJM, . Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161:1537–1547.
22.
GhaemiSN, WingoAP, FilkowskiMA, . Longterm antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand. 2008;118:347–356.
23.
GhaemiSN, LenoxMS, BaldessariniRJ.Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry. 2001;62:565–569.
24.
TrumanCJ, GoldbergJF, GhaemiSN, . Selfreported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry. 2007;68:1472–1479.
25.
BaldessariniRJ, TondoL, HennenJ, . Is lithium still worth using? An update of selected recent research. Harv Rev Psychiatry. 2002;10:59–75.
26.
GoodwinGM, BowdenCL, CalabreseJR, . A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry. 2004;65:432–441.
27.
HirschfeldRM, LewisL, VornikLA.Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64:161–174.
28.
MorselliPL, ElgieR, GAMIAN-Europe. GAMIAN-Europe/BEAM survey I–global analysis of a patient questionnaire circulated to 3450 members of 12 European advocacy groups operating in the field of mood disorders. Bipolar Disord. 2003;5:265–278.
29.
StrejilevichS, CorreaE.Costs and challenges of bipolar disorders: focus in the South American Region. J Affect Disord. 2007;98:165–167.
30.
GazalleFK, AndreazzaAC, CeresérKM, . Clinical impact of late diagnose of bipolar disorder. J Affect Disord. 2005;86:313–316.
31.
GoldbergJF, ErnstCL.Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry. 2002;63:985–991.
